Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Story 2 Small-Cap Biotechs That Could Reward Patient InvestorsSubmitted by Chris Markoch. Posted: 12/12/2025. 
In Brief - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. Nevertheless, if you're looking to invest in the small-cap biotech sector, patience is a requirement. Most, if not all, of these companies are still in the clinical stage, meaning they have no commercially available drugs or therapeutics. It also means these companies typically have negative earnings (i.e., are not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. Elon Musk's Starlink project is generating major speculation ahead of a potential IPO that some analysts believe could reach a historic $100 billion valuation. According to James Altucher, there may be a smart "backdoor" way for everyday investors to position ahead of that event without needing traditional IPO access — and he says it can be done for under $100. He's also sharing a free ticker tied to this trend for anyone who wants to take a closer look. Click here to learn more Even if a product advances through trials, profitability may still be years away. Only after reaching that milestone do companies typically attract analyst coverage and institutional investment. Still, getting in on one of these medical stocks and seeing it succeed can feel like winning the lottery. In an instant, investors could see 3x, 5x, or even 10x returns. Many others will never pan out, which is why investors who focus on penny stocks often spread a lump sum across many biotech names. If it's a numbers game, diversification can be an effective strategy. With that in mind, let's examine two small-cap biotech stocks that carry significant risks but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company that specializes in epigenetics-based tests for early cancer detection. Unlike many penny stocks in this space, Mainz Biomed has a commercially available product: ColoAlert—the first DNA-based screening tool for colorectal cancer available in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany's leading digital health pioneers. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is substantial. Mainz Biomed is also in early development of a non-invasive, blood-based screening test for the early detection of pancreatic cancer. The company reported positive topline results in October, but commercialization remains years away. The risks are material. ColoAlert is not yet available in the United States, and even with early sales in Europe and plans to expand into South America, revenue remains minimal. That's why the company included “Going Concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed has filed a $150 million mixed shelf offering. For now, that filing helps keep the MYNZ share price above $1 and avoids a delisting notice. The company is racing to generate enough revenue to move the needle. If successful, even a small investment could yield a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech that offers a potentially disruptive approach to antiviral treatment—but it also carries the financial risks speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These drug candidates are designed to mimic human cell surfaces and lure viruses to bind with them, effectively neutralizing the pathogens before they can infect cells. It's an innovative concept that, if validated in human trials, could represent a new method for treating infectious diseases. NanoViricides' current pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced, with encouraging preclinical data suggesting strong antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and reliant on fresh capital to advance programs. The company reported limited cash on hand in recent filings, so investors should expect the possibility of future dilution. Still, if one of its candidates advances successfully into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC stock represents a genuine moonshot in the antiviral space.
| 
